Centene-WellCare may face opposition from prominent hedge funds

Two major hedge funds that built stakes in Centene Corp. are considering challenging its proposed $17.3 billion bid for WellCare Health Plans, sources familiar with the matter told Reuters.

Advertisement

In the eyes of Corvex Management and Sachem Head Capital Management, Centene could do more to discover if another company may be interested in acquiring it, according to the sources. One possibility is Humana.

The Centene-WellCare deal requires shareholder approval to move forward, and the hedge funds may take advantage of that fact if they decide to oppose the merger, the sources told Reuters.

In a statement to Reuters, Centene spokesperson Marcela Hawn said, “We remain as committed to our combination with WellCare today as we did when we announced it on March 27.”

The American Hospital Association recently called on the Department of Justice’s Antitrust Division to investigate the deal.

More articles on payers:
Judge steps down from UnitedHealth case over ‘immoral’ denial of cancer treatment
House Democrats unveil Medicare expansion plan: 8 things to know
Humana posts $566M profit in Q1

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Transactions & Valuation Issues

Advertisement

Comments are closed.